Driehaus Capital GKOS Position
Exited5-Fund ConvergenceDriehaus Capital exited their position in Glaukos Corporation (GKOS) in Q3 2025, after holding the stock for 10 quarters.
The position was first reported in Q2 2023 and has been tracked across 10 quarterly 13F filings.
GKOS is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for GLK-321 low dose BID in 169 days (Sep 30, 2026), making the timing of Driehaus's position particularly relevant.
About Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Full company profile →Short Interest
7.3%
4.4 days to cover
Driehaus Capital GKOS Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q3 2025 | Exited | 0 | -500,472 | $0 |
| Q2 2025 | Decreased | 500,472 | -473,153 | $51.7M |
| Q1 2025 | Increased | 973,625 | +153,502 | $95.8M |
| Q4 2024 | Decreased | 820,123 | -41,484 | $123.0M |
| Q3 2024 | Increased | 861,607 | +57,957 | $112.3M |
| Q2 2024 | Increased | 803,650 | +155,653 | $95.1M |
| Q1 2024 | Increased | 647,997 | +59,144 | $61.1M |
| Q4 2023 | Increased | 588,853 | +99,288 | $46.8M |
| Q3 2023 | Increased | 489,565 | +1,283 | $36.8M |
| Q2 2023 | New | 488,282 | +488,282 | $34.8M |
Frequently Asked Questions
Does Driehaus Capital own GKOS?
No. Driehaus Capital exited their position in Glaukos Corporation (GKOS) in Q3 2025. They previously held the stock for 10 quarters.
How many hedge funds own GKOS?
5 specialist biotech hedge funds currently hold GKOS, including Deerfield Management, RTW Investments, Eventide Asset Management and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy GKOS?
Driehaus Capital's position in GKOS was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's GKOS position increasing or decreasing?
Driehaus Capital completely exited their GKOS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
GKOSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →